ReviewWiener medizinische Wochenschrift (1946)2009
[Anticoagulation in critically ill patient].
Review in Wiener medizinische Wochenschrift (1946), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Incidence of deep vein thrombosis in critically ill patients depends on the underlying disease but may be as high as 60%. In patients with severe sepsis or septic shock, Surviving Sepsis Campaign clearly recommends administering anticoagulation in the absence of specific contraindications. The article discusses risk factor for thromboembolic events in critical illness, non-pharmacological and pharmacological thrombosis prophylaxis as well as means of monitoring anticoagulation. Considering the ideal route of administration in intensive care patients, peripheral vasoconstriction, edema, shock, and administration of catecholamines may reduce bioavailability and efficacy of subcutaneous administration of low molecular weight heparin (LMWH). Dosing of the direct thrombin inhibitor argatroban depends on the severity of illness (SAPS II-score) and is up to 10-times lower than in patients without critical illness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.